C
Gossamer Bio, Inc. — Earnings Quality Grade C
GOSS · Healthcare
Some red flags
Revenue
$48M
2025
Net Income
-$170M
2025
Gross Margin
—
Free Cash Flow
-$171M
01
Screening Summary
7
Passed
4
Watch
0
Failed
—
M-Score
管理层信号
最近 SEC 8-K 文件中未发现 CEO、CFO、董事会或审计负责人变动信号。
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
✓
A3Revenue vs CFFO
Revenue -57.7%, CFFO -4838.5%. Cash follows revenue
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
—
B2CapEx vs Revenue
Insufficient data
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✓
C1CFFO vs Net Income
CFFO/NI = 1.01. Profits backed by cash
!
C2Free Cash Flow
FCF is negative ($-0.2B)
✓
C3Accruals Ratio
Accruals ratio = 0.5%. Low accruals
!
C4Cash vs Debt
Cash $0.1B covers 67% of debt $0.2B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
!
D2Leverage
Interest coverage = -14.9x (<2x). Financial stress
!
D3Soft Asset Growth
Other assets grew 44.2% vs revenue -57.7%
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
✓
E1Serial Acquirer FCF
FCF after acquisitions positive
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
-29.92
Distress Zone0 Distress1.102.605.0+ Safe
0.605
Liquidity
-8.3538
Cumulative profit
-0.9258
Operating efficiency
-0.4161
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25